Who are Dexmedetomidine Injectable Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): treatment with brimonidine/timolol, High-dose dexmedetomidine, alpha methyldopa, Dexmedetomidine 0.75 microgram/kg, Group D : Dexmedetomidine + propofol group, Dexmedetomidine (DEX).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexmedetomidine-injectable-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dexmedetomidine Injectable Product — Competitive Intelligence Brief

Dexmedetomidine Injectable Product (Dexmedetomidine Injectable Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Anesthesia and Sedation.

phase 3 Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Anesthesia and Sedation Small molecule Live · refreshed every 30 min

Target snapshot

Dexmedetomidine Injectable Product (Dexmedetomidine Injectable Product) — Eye & ENT Hospital of Fudan University. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dexmedetomidine Injectable Product TARGET	Dexmedetomidine Injectable Product	Eye & ENT Hospital of Fudan University	phase 3	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
treatment with brimonidine/timolol	treatment with brimonidine/timolol	Aristotle University Of Thessaloniki	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
High-dose dexmedetomidine	High-dose dexmedetomidine	Tang-Du Hospital	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
alpha methyldopa	alpha methyldopa	Radboud University Medical Center	marketed	Central-acting alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Dexmedetomidine 0.75 microgram/kg	Dexmedetomidine 0.75 microgram/kg	Sindh Institute of Urology and Transplantation	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Group D : Dexmedetomidine + propofol group	Group D : Dexmedetomidine + propofol group	Seoul National University Hospital	marketed	Sedative-hypnotic combination (alpha-2 agonist + GABA-A agonist)	Alpha-2 adrenergic receptor (dexmedetomidine); GABA-A receptor (propofol)
Dexmedetomidine (DEX)	Dexmedetomidine (DEX)	Ain Shams University	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

Allergan · 3 drugs in this class
Eye & ENT Hospital of Fudan University · 2 drugs in this class
National Cancer Institute, Egypt · 2 drugs in this class
The University of Hong Kong · 2 drugs in this class
Sindh Institute of Urology and Transplantation · 2 drugs in this class
Fayoum University Hospital · 1 drug in this class
First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
KAT General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexmedetomidine Injectable Product — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-injectable-product. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab